Cargando…
A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs
PURPOSE: The advent of genomic diagnostic technologies such as next-generation sequencing has recently enabled the use of genomic information to guide targeted treatment in patients with cancer, an approach known as precision medicine. However, clinical outcomes, including survival and the cost of h...
Autores principales: | Haslem, Derrick S., Van Norman, S. Burke, Fulde, Gail, Knighton, Andrew J., Belnap, Tom, Butler, Allison M., Rhagunath, Sharanya, Newman, David, Gilbert, Heather, Tudor, Brian P., Lin, Karen, Stone, Gary R., Loughmiller, David L., Mishra, Pravin J., Srivastava, Rajendu, Ford, James M., Nadauld, Lincoln D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455156/ https://www.ncbi.nlm.nih.gov/pubmed/27601506 http://dx.doi.org/10.1200/JOP.2016.011486 |
Ejemplares similares
-
Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs
por: Haslem, Derrick S., et al.
Publicado: (2018) -
Universal Germline Testing of Unselected Cancer Patients Detects Pathogenic Variants Missed by Standard Guidelines without Increasing Healthcare Costs
por: Perkins, Adrienne T., et al.
Publicado: (2021) -
Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2–Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine
por: Haslem, Derrick S., et al.
Publicado: (2017) -
An elevated neutrophil-to-lymphocyte ratio associates with weight loss and cachexia in cancer
por: Barker, Tyler, et al.
Publicado: (2020) -
Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer
por: Xia, Li C., et al.
Publicado: (2020)